The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.
Parsippany, New Jersey–based Ascensia is Senseonics’ global commercial partner. Alongside the Eversense E3, Asensia launched the Eversense PASS savings program to increase patient access to the CGM and its benefits, according to a news release. The company designed Eversense PASS to allow users to pay only $99 out of pocket for their first Eversense E3 sensor and smart transmitter and, for each sensor thereafter, users pay no more than $100 per month or $600 for the duration of each sensor wear.
“We are thrilled to offer Eversense E3 to people with diabetes in the U.S. and are proud to do this alongside a favorable Payment Assistance and Savings Program,” Ascensia Diabetes Care President Robert Schumm said in the release. “As the longest-lasting CGM system available at up to 6 months of sensor wear, Eversense E3’s offering is truly differentiated, and we believe it is important to make the system as affordable as possible.”
Senseonics presented data in 2021 that demonstrated strong accuracy with the fully implantable, 180-day sensor. The next-generation platform matched performance levels compared to the 90-day version, but with calibration reduced to essentially once per day. One of the sensor’s tests produced a mean absolute relative difference (MARD) of 8.5%, representing high accuracy.
Eversense E3 features a third-generation sensor with SBA technology that enhances sensor longevity to make it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.
“The evolution of continuous glucose monitoring has been one of the biggest developments in diabetes care and the Eversense E3 CGM System is another significant step forward for patients,” Ascensia’s Head of the Eversense CGM business unit Elaine Anderson said. “It’s so important to offer choice through a variety of solutions and to listen to what people really need from technology to live life as fully as possible. Eversense E3 exemplifies this approach, offering people with diabetes an exciting new CGM option with outstanding flexibility, convenience and accuracy.”